Geetha Bhat1, Gardner Yost2, Edward Mahoney2. 1. Center for Heart Transplant and Assist Devices, Advocate Christ Medical Center, Oak Lawn, Illinois. Electronic address: Geetha.Bhat@advocatehealth.com. 2. Center for Heart Transplant and Assist Devices, Advocate Christ Medical Center, Oak Lawn, Illinois.
Abstract
BACKGROUND: Cognitive impairment is frequent in patients with heart failure (HF) and can lead to poor quality of life and increased risk of mortality. The Montreal Cognitive Assessment (MoCA) is a simple screening tool that is sensitive to mild cognitive impairment (MCI) and that has been validated in the settings of neurologic and cardiovascular disease. This study determined the extent of cognitive impairment in patients with HF undergoing evaluation for advanced surgical therapy and evaluated changes in MoCA score with follow-up cognitive assessment at 8 months after left ventricular assist device (LVAD) implantation. METHODS: As part of routine assessment for LVAD candidacy, 176 patients with advanced HF were administered the MoCA; 56 patients were reevaluated 8 months after LVAD implantation. RESULTS: Patients with MCI, indicated by MoCA score <26 out of 30, made up 67% of the study cohort. MCI was associated with significantly older age, higher CHADS2 (congestive HF, hypertension, age >75 years, diabetes mellitus, prior stroke or transient ischemic attack) risk score, statin use, history of stroke and hypertension, and reduced serum cholesterol levels. In 56 patients who underwent follow-up evaluation after LVAD implantation, total MoCA score and visuospatial, executive, and delayed recall cognitive domains were significantly improved. CONCLUSIONS: This study assessed the use of the MoCA in patients with end-stage HF being evaluated for advanced surgical therapy. We found the MoCA to be a rapid, simple, and powerful tool for detecting cognitive impairment in these patients. MCI was highly prevalent in the cohort. Significant improvement in overall MoCA score was noted after LVAD implantation.
BACKGROUND:Cognitive impairment is frequent in patients with heart failure (HF) and can lead to poor quality of life and increased risk of mortality. The Montreal Cognitive Assessment (MoCA) is a simple screening tool that is sensitive to mild cognitive impairment (MCI) and that has been validated in the settings of neurologic and cardiovascular disease. This study determined the extent of cognitive impairment in patients with HF undergoing evaluation for advanced surgical therapy and evaluated changes in MoCA score with follow-up cognitive assessment at 8 months after left ventricular assist device (LVAD) implantation. METHODS: As part of routine assessment for LVAD candidacy, 176 patients with advanced HF were administered the MoCA; 56 patients were reevaluated 8 months after LVAD implantation. RESULTS:Patients with MCI, indicated by MoCA score <26 out of 30, made up 67% of the study cohort. MCI was associated with significantly older age, higher CHADS2 (congestive HF, hypertension, age >75 years, diabetes mellitus, prior stroke or transient ischemic attack) risk score, statin use, history of stroke and hypertension, and reduced serum cholesterol levels. In 56 patients who underwent follow-up evaluation after LVAD implantation, total MoCA score and visuospatial, executive, and delayed recall cognitive domains were significantly improved. CONCLUSIONS: This study assessed the use of the MoCA in patients with end-stage HF being evaluated for advanced surgical therapy. We found the MoCA to be a rapid, simple, and powerful tool for detecting cognitive impairment in these patients. MCI was highly prevalent in the cohort. Significant improvement in overall MoCA score was noted after LVAD implantation.
Authors: Marykay A Pavol; Joshua Z Willey; Ying Wei; Melana Yuzefpolskaya; Randolph S Marshall; Philip J Marascalco; Jason Harwood; Ronald M Lazar Journal: Gen Thorac Cardiovasc Surg Date: 2018-05-23
Authors: Evgenij V Potapov; Christiaan Antonides; Maria G Crespo-Leiro; Alain Combes; Gloria Färber; Margaret M Hannan; Marian Kukucka; Nicolaas de Jonge; Antonio Loforte; Lars H Lund; Paul Mohacsi; Michiel Morshuis; Ivan Netuka; Mustafa Özbaran; Federico Pappalardo; Anna Mara Scandroglio; Martin Schweiger; Steven Tsui; Daniel Zimpfer; Finn Gustafsson Journal: Eur J Cardiothorac Surg Date: 2019-08-01 Impact factor: 4.191
Authors: Fang Qin Goh; William K F Kong; Raymond C C Wong; Yao Feng Chong; Nicholas W S Chew; Tiong-Cheng Yeo; Vijay Kumar Sharma; Kian Keong Poh; Ching-Hui Sia Journal: Biology (Basel) Date: 2022-01-23
Authors: Cecilia Berardi; Claudio A Bravo; Song Li; Maziar Khorsandi; Jeffrey E Keenan; Jonathan Auld; Sunny Rockom; Jennifer A Beckman; Claudius Mahr Journal: J Clin Med Date: 2022-04-05 Impact factor: 4.241
Authors: Anirudh Rao; Manavotam Singh; Mansi Maini; Kelley M Anderson; Nancy A Crowell; Paul R Henderson; Sherry S Gholami; Farooq H Sheikh; Samer S Najjar; Hunter Groninger Journal: Front Cardiovasc Med Date: 2022-08-30
Authors: Mateusz G Adamski; Magdalena Sternak; Tasnim Mohaissen; Dawid Kaczor; Joanna M Wierońska; Monika Malinowska; Iwona Czaban; Katarzyna Byk; Kristina S Lyngsø; Kamil Przyborowski; Pernille B L Hansen; Grzegorz Wilczyński; Stefan Chlopicki Journal: J Am Heart Assoc Date: 2018-03-26 Impact factor: 5.501